Business
Aurora Cannabis and CTT Pharmaceutical Announce Launch of Sublingual Cannabis Wafers
Aurora Cannabis and CTT Pharmaceutical Announce Launch of Sublingual Cannabis Wafers.
About this update from Ctt Pharmaceutical Holdings, Inc.
[{"type":"text","content":"\n\n\n\nAurora Cannabis and CTT Pharmaceutical Announce Launch of Sublingual Cannabis Wafers\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prngen2{\nBORDER-TOP:black 0pt; BORDER-RIGHT:black 0pt; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM:black 0pt; PADDING-LEFT:0.50em; BORDER-LEFT:black 0pt; PADDING-RIGHT:0.50em\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n.prnsbt0{\nBORDER-TOP:0pt\n}\n.prnbcc{\nBORDER-COLLAPSE: COLLAPSE\n}\n.prnsbl0{\nBORDER-LEFT:0pt\n}\n.prnsbb0{\nBORDER-BOTTOM:0pt\n}\n.prnsbr0{\nBORDER-RIGHT:0pt\n}\n\n\n\n\n\n\nAurora Cannabis and CTT Pharmaceutical Announce Launch of Sublingual Cannabis Wafers\nPR Newswire\nEDMONTON and HAMILTON, ON, Oct. 8, 2019\n\n\n\nDissolve Strips ™ Now Available to Aurora's Canadian Medical Patients\nNYSE | TSX: ACB OTC: CTTH \n EDMONTON and HAMILTON, ON, Oct. 8, 2019 /PRNewswire/ - Aurora Cannabis Inc. (\"Aurora\") (NYSE | TSX: ACB), the Canadian company defining the future of cannabis worldwide, and CTT Pharmaceutical Holdings, Inc., (\"CTT\") (OTC | CTTH) announced today the successful commercialization of CTT's cannabinoid-infused sublingual wafers. The new cannabis product line, a first of its kind, has been launched by Aurora in the Canadian medical cannabis market under the brand name \"Dissolve Strips™\". \nAurora has an ownership interest in CTT of approximately 9%, with a warrant allowing it to increase its stake to 42.5%, and access to CTT's sublingual wafers drug delivery technology, which is patent protected or patent pending in multiple jurisdictions.\n\"Aurora's Dissolve Strips™ provide unique advantages over other ingestible products due to their ease of administration, discrete nature and accurate dosage, that provides more rapid bioavailability of cannabinoids via sublingual use,\" said Terry Booth, CEO of Aurora. \"This adds yet another innovative offering to our growing portfolio of high quality, medical products that we offer our patient base, and is testament to our industry leading ability to work with technology partners and regulators to bring new form factors to market rapidly.\"\nCTT's CEO Cam Birge, adde...